Lymph Nodes News and Research

RSS

MR-guided ultrasound may offer safe and effective treatment for breast cancer

A technique that uses focused ultrasound under magnetic resonance guidance to heat and destroy tumors may offer a safe and effective treatment for breast cancer, according to research being presented today at the annual meeting of the Radiological Society of North America.

4 Dec 2013

Frequent mammography screening reduces the rate of lymph node positivity

In a study of screening mammography-detected breast cancers, patients who had more frequent screening mammography had a significantly lower rate of lymph node positivity—or cancer cells in the lymph nodes—as compared to women who went longer intervals between screening mammography exams.

4 Dec 2013

Toshiba's new ultrasound technology depicts blood flow with more detail and accuracy

Ultrasound will be able to depict blood flow with more detail and accuracy using Toshiba America Medical Systems, Inc.'s new innovative ultrasound technology (works-in-progress).

3 Dec 2013

NEXAVAR tablets receive FDA approval for treatment of patients with thyroid cancer

Bayer HealthCare and Onyx Pharmaceuticals, Inc., an Amgen subsidiary, today announced that the U.S. Food and Drug Administration has approved a supplemental New Drug Application for the oral multi-kinase inhibitor NEXAVAR (sorafenib) tablets for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment.

23 Nov 2013

Treatment of pelvic nodes can be easily integrated into IMRT-based treatment strategy

Treatment of pelvic nodes individualized by inclusion of sentinel nodes can be easily integrated into an IMRT-based treatment strategy, according to the new study conducted by a group of researchers from T-bingen and Munich in Germany. The target volume concept seems to correctly cover individual pelvic nodes, which is indicated by the absence of any nodal recurrence within five years of follow-up.

18 Nov 2013

Imbruvica gets FDA approval for treatment of mantle cell lymphoma

The U.S. Food and Drug Administration today approved Imbruvica (ibrutinib) to treat patients with mantle cell lymphoma, a rare and aggressive type of blood cancer.

13 Nov 2013

CTCA doctor presents cutting-edge treatments for cancer patients to medical colleagues

Walter Quan, Jr., MD Chief of Medical Oncology and Director of Immunotherapy at Cancer Treatment Centers of America- Western Regional Medical Center is presenting new findings that are showing a major benefit to cancer patients.

11 Nov 2013

Nanomedicine Award winners officially announced at BIO-Europe conference

The winners of the first ever Nanomedicine Award were officially announced during the Nanomedicine Panel at BIO-Europe conference in Vienna, November 4th 2013. The Award review Board agreed to distinguish two projects in two different categories: The winners are Endomagnetics Ltd in the nanodiagnostic category and the I-CARE project from Linköping University in the regenerative medicine category.

4 Nov 2013

FDG-PET parameter predicts locally advanced lung cancer survival

High post-treatment concentrations of a radioactive imaging marker are predictive of worse overall survival from inoperable, locally advanced non-small-cell lung cancer, prospective study findings suggest.

31 Oct 2013

Penn Medicine researchers show predictive power of overlooked lymph nodes

For the first time, researchers from the Perelman School of Medicine at the University of Pennsylvania have shown the predictive power of a group of overlooked lymph nodes--known as the posterior intercostal lymph nodes--that could serve as a better tool to stage and ultimately treat patients with malignant pleural mesothelioma.

29 Oct 2013

Rituximab drug may be safe, effective for immunoglobulin G4-related disease treatment

Rituximab (Rituxan) — a drug commonly used rheumatoid arthritis, granulomatosis with polyangiitis (formerly Wegener's), and certain types of cancers — may be a safe and effective treatment for immunoglobulin G4-related disease (commonly called IgG4-RD), according to research presented this week at the American College of Rheumatology Annual Meeting in San Diego.

28 Oct 2013

Scientists reveal first comprehensive genomic analysis of aggressive lymphomas

Mantle cell lymphoma is a very aggressive and difficult to treat cancer originated in blood cells and lymph nodes. To identify the molecular alterations responsible for this tumor, and facilitate the development of new treatments, a team of scientists led by Dr. Xose S. Puente and Dr. Carlos López-Otín, at University of Oviedo, and Dr. Sílvia Beà and Dr. Elias Campo, at IDIBAPS, Hospital Clínic, University of Barcelona, have sequenced the genomes of over 30 of lymphomas.

23 Oct 2013

Ultrasound prior to thyroidectomy important for planning surgery

Ultrasound imaging is commonly used to diagnose and evaluate patients with differentiated thyroid cancer, and to determine whether the disease has spread to lymph nodes in the neck that should be removed at the time of thyroidectomy.

17 Oct 2013

Breast cancer patients receiving nerve block with general anesthesia have less cancer recurrence

Breast cancer patients who received the combination of a nerve block with general anesthesia for their breast cancer surgery had less cancer recurrence and were three times less likely to die than those who received only general anesthesia, according to a study presented at the ANESTHESIOLOGY 2013 annual meeting.

16 Oct 2013

Clinical study to determine sentinel lymph node surgery in patients with breast cancer

Judy C. Boughey, M.D., Kelly K. Hunt, M.D., and colleagues for the Alliance for Clinical Trials in Oncology conducted a study to determine the false-negative rate of sentinel lymph node surgery in patients with node-positive breast cancer receiving chemotherapy before surgery.

8 Oct 2013

Less-invasive procedure identifies cancer remains in lymph nodes after chemotherapy

Most patients whose breast cancer has spread to their lymph nodes have most of the lymph nodes in their armpit area removed after chemotherapy to determine if any cancer remains.

8 Oct 2013

New biomarker for pancreatic cancer effectively targets potential therapy for small survival rate

University of Cincinnati (UC) researchers have discovered a biomarker, known as phosphatidylserine (PS), for pancreatic cancer that could be effectively targeted, creating a potential therapy for a condition that has a small survival rate.

5 Oct 2013

UCSD surgeons perform first robotic gastrectomy for gastric cancer treatment

Surgeons at UC San Diego Health System have performed the region's first robotic gastrectomy, a potentially lifesaving procedure to remove a section of the stomach after a diagnosis of gastric cancer. Aided by a da Vinci robot, surgeons remove the diseased tissue, perform a delicate reconstruction and remove local lymph nodes for further testing.

3 Oct 2013

FDA grants accelerated approval of Perjeta for people with HER2-positive early stage breast cancer

The U.S. Food and Drug Administration granted accelerated approval of a Perjeta- (pertuzumab) regimen for neoadjuvant treatment (use before surgery) in people with high-risk, HER2-positive early stage breast cancer.

2 Oct 2013

FDA grants accelerated approval to Perjeta for neoadjuvant treatment of breast cancer

The U.S. Food and Drug Administration today granted accelerated approval to Perjeta (pertuzumab) as part of a complete treatment regimen for patients with early stage breast cancer before surgery (neoadjuvant setting). Perjeta is the first FDA-approved drug for the neoadjuvant treatment of breast cancer.

1 Oct 2013